Delivery Order SPE2DR25D9131-SPE2DR26FCPD4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $79,695.84 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award, issued on November 10, 2025, with an ultimate completion date of November 12, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $18,868.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. The contract, issued on November 6, 2025, with an ultimate completion date of November 7, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order represents one of numerous purchase orders...
- The Defense Logistics Agency issued a $95,242.06 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award, issued on November 28, 2025, with an ultimate completion date of December 1, 2025, represents a routine pharmaceutical delivery under the agency's medical supply operations. DMS Pharmaceutical Group was selected...
- The Defense Logistics Agency awarded a delivery order valued at $18,488.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). Issued on November 6, 2025, with an ultimate completion date of November 7, 2025, this firm fixed-price delivery order carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency issued a delivery order valued at $37,736.66 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This firm fixed-price delivery order, awarded on December 5, 2025, with an ultimate completion date of December 8, 2025, was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,474.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 50-25-37.5 mg/75 mg tablets (84 count). This delivery order, issued November 4, 2025, with an ultimate completion date of November 5, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in...
- The Defense Logistics Agency awarded a delivery order valued at $18,488.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. This firm fixed-price delivery order, issued on October 29, 2025, with an ultimate completion date of October 30, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $94,763.11 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This firm fixed-price delivery order, issued on December 4, 2025, with an ultimate completion date of December 5, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in...
- The Defense Logistics Agency awarded a delivery order valued at $38,633.14 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg tablets in quantities of 14 packets. The delivery order, issued on October 23, 2025, with an ultimate completion date of October 24, 2025, operates under a firm fixed-price structure with no set-aside designation. This award represents a single transaction within...
- The Defense Logistics Agency awarded a $37,722.26 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This delivery order, issued on December 8, 2025, with an ultimate completion date of December 9, 2025, represents a routine pharmaceutical procurement under DLA's Medical Supply Chain operations. No set-aside designation...
- SPE2DR25D9131Indefinite Delivery Contract
- SPE2DR25D9131-SPE2DR26FCPD4Delivery Order
The Defense Logistics Agency has awarded a delivery order valued at $18,868.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This firm fixed-price delivery order, issued on December 3, 2025, with an ultimate completion date of December 4, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors for the Department of Defense's pharmaceutical supply chain. DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier to the federal military medical system through consistent performance on numerous delivery orders since its IDC award on November 13, 2025. The parent contract, designated SPE2DR, carries a $500 million ceiling and extends through December 31, 2036, structured with a 30-month base period and three 30-month option periods. The company's product portfolio spans branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it to support the diverse healthcare requirements of Department of Defense facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.9k | 12/2/25 |